All In Biotech

Free tool

FAERS Monitor: Jubbonti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761362 or its brand name (Jubbonti, Denosumab-Bbdz). Reports on generic versions are filed under their own applications.

Reports

16,950

Serious

16,209

96% of reports

Hospitalization

6,904

Death reported

2,031

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • osteonecrosis of jaw1,555
  • diarrhoea1,184
  • fatigue1,152
  • nausea1,101
  • malignant neoplasm progression1,072
  • neutropenia981
  • metastases to bone858
  • off label use847
  • anaemia759
  • vomiting627
  • dyspnoea611
  • hypocalcaemia611
  • decreased appetite608
  • death596
  • arthralgia566

Reports by year received

View as table
YearReports
20081
20092
201067
2011136
2012214
2013358
2014474
2015662
2016748
2017636
2018956
20191,013
20201,063
20211,495
20221,772
20231,782
20241,733
20251,823
20262,015

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,209 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
osteonecrosis of jawSignal1,55583.179.1118,318
metastases to boneSignal85868.463.953,974
hypocalcaemiaSignal61141.438.223,268
malignant neoplasm progressionSignal1,07213.112.411,919
neutropeniaSignal9819.08.56,973
anaemiaSignal7595.04.62,404
decreased appetiteSignal6083.33.0955
diarrhoeaSignal1,1842.32.2873
fatigue1,1521.81.7455
nausea1,1011.71.6349
arthralgia5661.71.6162
vomiting6271.71.5166
dyspnoea6111.31.254
off label use8471.21.129
death5960.90.814

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.